Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke - The Systolic Hypertension in the Elderly Program (SHEP)

Citation
Hm. Perry et al., Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke - The Systolic Hypertension in the Elderly Program (SHEP), J AM MED A, 284(4), 2000, pp. 465-471
Citations number
21
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
ISSN journal
00987484 → ACNP
Volume
284
Issue
4
Year of publication
2000
Pages
465 - 471
Database
ISI
SICI code
0098-7484(20000726)284:4<465:EOTISH>2.0.ZU;2-T
Abstract
Context The Systolic Hypertension in the Elderly Program (SHEP) demonstrate d that treating isolated systolic hypertension in older patients decreased incidence of total stroke, but whether all types of stroke were reduced was not evaluated. Objective To investigate antihypertensive drug treatment effects on inciden ce of stroke by type and subtype, timing of strokes, case-fatality rates, s troke residual effects, and relationship of attained systolic blood pressur e to stroke incidence. Design The SHEP study, a randomized, double-blind, placebo-controlled trial began March 1, 1985, and had an average follow-up of 4.5 years. Setting and Participants A total of 4736 men and women aged 60 years or old er with isolated systolic hypertension at 16 clinical centers in the United States. Interventions Patients were randomly assigned to receive treatment with 12. 5 mg/d of chlorthalidone (step 1); either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be added (n = 2365); or placebo (n = 2371). Main Outcome Measures Occurrence, type and subtype, and timing of first str okes and stroke fatalities; and change in stroke incidence for participants (whether in active treatment or placebo groups) reaching study-specific sy stolic blood pressure goal (decrease of at least 20 mm Hg from baseline to below 160 mm Hg) compared with participants not reaching goal. Results A total of 85 and 132 participants in the active treatment and plac ebo groups, respectively, had ischemic strokes (adjusted relative risk [RR] , 0.63; 95% confidence interval [CI], 0.48-0.82); 9 and 19 had hemorrhagic strokes (adjusted RR, 0.46; 95% CI, 0.21-1.02); and 9 and 8 had strokes of unknown type (adjusted RR, 1.05; 95% CI, 0.40-2.73), respectively. Four sub types of ischemic stroke were observed in active treatment and placebo grou p participants, respectively, as follows: for lacunar, n=23 and n=43 (adjus ted RR, 0.53; 95% CI, 0.32-0.88); for embolic, n=9 and n=16 (adjusted RR, 0 .56; 95% CI, 0.25-1.27); for atherosclerotic, n=13 and n=13 (adjusted RR, 0 .99; 95% CI, 0.46-2.15); and for unknown subtype, n=40 and n=60 (adjusted R R, 0.64; 95% CI, 0.43-0.96). Treatment effect was observed within 1 year fo r hemorrhagic strokes but was not seen until the second year for ischemic s trokes. Stroke incidence significantly decreased in participants attaining study-specific systolic blood pressure goals. Conclusions In this study, antihypertensive drug treatment reduced the inci dence of both hemorrhagic and ischemic (including lacunar) strokes. Reducti on in stroke incidence occurred when specific systolic blood pressure goals were attained.